The Ohio State University Medical Center, 395 W, 12th Avenue, Columbus, OH 43210, USA.
J Hematol Oncol. 2008 Oct 17;1:18. doi: 10.1186/1756-8722-1-18.
Hepatocellular carcinoma is rare, but increasing in prevalence in the United States. Recent studies have shown that sorafenib, a multikinase inhibitor, can reduce tumor progression in patients with this cancer. However, complete remission has not been observed. We report a case of a 78-year old patient with unresectable metastatic hepatocellular carcinoma who had a rapid and complete clinical response following therapy with sorafenib for six months. No evidence of disease recurrence has been noted for 6 months after discontinuation of therapy.
肝细胞癌较为罕见，但在美国的发病率呈上升趋势。最近的研究表明，多激酶抑制剂索拉非尼可减少此类癌症患者的肿瘤进展。但尚未观察到完全缓解。我们报告了一例 78 岁不可切除转移性肝细胞癌患者，该患者在接受索拉非尼治疗 6 个月后获得了快速和完全的临床缓解。在停止治疗后 6 个月，未发现疾病复发的迹象。
